Stroke Drug Development Targeting Guanosine

Studies have shown that guanosine can play a neurotrophic and neuroprotective role during ischemic stroke through anti-inflammatory, anti-apoptotic, antioxidant, neurogenesis-promoting, and other activities. Therefore, given the various protective effects of guanosine on stroke pathological processes, it is considered as a potential stroke therapeutic agent. Several studies have shown that exogenous guanosine administered in vivo can indeed alleviate the damage caused by stroke in the organism. Therefore, for the therapeutic activity of guanosine, Ace Therapeutics offers comprehensive services to target guanosine for stroke drug development.

Discovery of Guanosine Derivatives

Based on the heterocyclic structure of guanosine containing nitrogen atoms, guanosine derivatives are usually produced by modifying or extending the bases of guanosine. Therefore, Ace Therapeutics provides high-quality services for the discovery of guanosine derivatives based on the principles of pharmacological activity and drug toxicity. By modifying guanosine, potential guanosine-based stroke drugs can be enriched and the success rate of drug development can be greatly improved.

Exploration of The Mode of Administration of Guanosine & Its Derivatives

Intracerebral administration is the most targeted modality while producing fewer effects on the organism, but systemic administration is the most convenient modality. Therefore, Ace Therapeutics has established different protocols for different delivery routes to screen for the optimal delivery mode for each drug candidate.

• Intracerebral delivery Targeting the brain delivery system, transnasal delivery, intrathecal / intracerebroventricular delivery, blood brain barrier disruption
• Systemic delivery Oral, intraperitoneal, intravenous, subcutaneous, intramuscular

In addition, guanosine acting by systemic administration immediately after stroke onset is effective in preventing ischemic injury. Recent studies have shown that the intranasal route of administration expands the therapeutic window of guanosine and that administration within 3 h after stroke is equally effective in preventing behavioral deficits and brain injury. Therefore, we further explore the effects of other routes of administration for stroke treatment at different times of administration.

• We establish different animal models of stroke and investigate the differences in their effects by setting different time points of administration in combination with different routes of administration.
• We perform comprehensive tests on the model animals to assess the protective effect of different drug delivery modes on stroke.

Preclinical Evaluation of Drug Candidates for the Treatment of Stroke

Ace Therapeutics provides high-quality services to perform comprehensive preclinical drug development evaluations of guanosine and its analogs.

• For guanosine derivatives obtained by modification of guanosine, we initially evaluate the therapeutic efficacy of drug candidates against stroke through in vitro stroke models to screen for potential therapeutic activity.
• For potential drug candidates, we validate their effects on different stroke conditions by different in vivo stroke models and perform comprehensive pharmacological evaluation of the drug candidates by pathological examination, behavioral test evaluation, and other assay services.
• Based on in vitro or in vivo models of guanosine action, we provide comprehensive mechanistic study services at the gene and protein level to elucidate the specific effects of guanosine on different stroke conditions.

For the development of stroke drugs and therapies targeting guanosine, we offer a high-quality and comprehensive biotechnology service. If you would like to learn more about our services, please feel free to contact us.

1. Chojnowski, K., et al., Neuroprotective effects of guanosine in ischemic stroke-small steps towards effective therapy. Int J Mol Sci, 2021. 22(13).